AU2002222932A1 - N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists - Google Patents

N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists

Info

Publication number
AU2002222932A1
AU2002222932A1 AU2002222932A AU2293202A AU2002222932A1 AU 2002222932 A1 AU2002222932 A1 AU 2002222932A1 AU 2002222932 A AU2002222932 A AU 2002222932A AU 2293202 A AU2293202 A AU 2293202A AU 2002222932 A1 AU2002222932 A1 AU 2002222932A1
Authority
AU
Australia
Prior art keywords
cyclylamine
hydroxyethylamines
sulfonylaryl
beta
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222932A
Inventor
Michael Sotirios Malamas
Fuk-Wah Sum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2002222932A1 publication Critical patent/AU2002222932A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002222932A 2000-07-17 2001-07-16 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists Abandoned AU2002222932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21858900P 2000-07-17 2000-07-17
US60218589 2000-07-17
PCT/US2001/022379 WO2002006274A1 (en) 2000-07-17 2001-07-16 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
AU2002222932A1 true AU2002222932A1 (en) 2002-01-30

Family

ID=22815690

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222932A Abandoned AU2002222932A1 (en) 2000-07-17 2001-07-16 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists

Country Status (3)

Country Link
US (2) US6444685B1 (en)
AU (1) AU2002222932A1 (en)
WO (1) WO2002006274A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798126B1 (en) * 1999-09-08 2001-10-19 Sanofi Synthelabo HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP4782342B2 (en) * 1999-12-17 2011-09-28 サノフィ−アベンティス Phenoxypropanolamines, processes for their production and pharmaceutical compositions containing them
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
US6797707B2 (en) 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
NZ540612A (en) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1927594A1 (en) 2003-01-14 2008-06-04 Arena Pharmaceuticals, Inc. 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CA2539541C (en) * 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2007042912A2 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
EP2128134A1 (en) * 2006-11-02 2009-12-02 Shionogi&Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US9067947B2 (en) * 2009-01-16 2015-06-30 Universal Display Corporation Organic electroluminescent materials and devices
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
MX353105B (en) 2010-08-03 2017-12-19 Velicept Therapeutics Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder.
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8865660B2 (en) 2010-12-10 2014-10-21 Broady Health Sciences, Llc Method of treating neurogenic overactive bladder in a mammal or method of treating non-psychological stress-related bladder dysfunction in a female mammal by administering at least on jasmonate
KR20170086659A (en) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP4445956A2 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
CN108290824B (en) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 Sorabegron zwitterion and application thereof
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2021042126A (en) * 2017-12-27 2021-03-18 佐藤製薬株式会社 Aryloxy compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
EP0449261A3 (en) 1990-03-29 1992-02-26 Kabushiki Kaisha Toshiba Resin composition for an optical disc and an optical disc using it
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
JP3926390B2 (en) 1995-10-26 2007-06-06 三菱ウェルファーマ株式会社 Phenylethanolamine compounds useful as β3 agonists, their production and intermediates in their production
PL341379A1 (en) * 1997-11-14 2001-04-09 Searle & Co Aromatic sulphone substituted hydroxamic acid as inhibitor of metalloprotease
FR2780057B1 (en) 1998-06-18 2002-09-13 Sanofi Sa PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2798126B1 (en) 1999-09-08 2001-10-19 Sanofi Synthelabo HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP4782342B2 (en) 1999-12-17 2011-09-28 サノフィ−アベンティス Phenoxypropanolamines, processes for their production and pharmaceutical compositions containing them
FR2802533B1 (en) 1999-12-17 2002-02-15 Sanofi Synthelabo PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
US20020028797A1 (en) 2002-03-07
US20030027795A1 (en) 2003-02-06
WO2002006274A1 (en) 2002-01-24
US6743787B2 (en) 2004-06-01
US6444685B1 (en) 2002-09-03

Similar Documents

Publication Publication Date Title
AU2002222932A1 (en) N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
AU2002222930A1 (en) Cyclic amine phenyl beta-3 adrenergic receptor agonists
AU2001280568A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
AU2002222929A1 (en) Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
IL154911A0 (en) Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
ATE430124T1 (en) ARYLANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS
AU2001275946A1 (en) Substituted 2-(s)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(r)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine beta-3 adrenergic receptor agonists
AU2001273728A1 (en) Arrangement for connecting planar components
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
AU5203999A (en) Beta3-adrenergic receptor agonists
AU2001273515A1 (en) Azolidines as beta-3 adrenergic receptor agonists
AU2003243637A1 (en) Cannabinoid receptor agonists
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
AU2001273508A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
AU2001273542A1 (en) 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2001246934A1 (en) Agonist antibodies
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2001248998A1 (en) Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1- naphthalenemethanamine (terbinafine)
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2001273501A1 (en) Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
AU2001273516A1 (en) Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
AUPQ563400A0 (en) Novel receptor
AU2001271933A1 (en) Alpha,alpha-dibromo-alpha-chloro-acetophenones as synthons
AU2002346030A1 (en) Novel receptors